MRI mimics of multiple sclerosis.

Handb Clin Neurol

Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands.

Published: September 2014


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Diagnosis of multiple sclerosis (MS) is based on the demonstration of dissemination of lesions in space (DIS) and in time (DIT), as well as on the exclusion of an alternative neurologic disorder. As a paraclinical tool brain and/or spinal cord magnetic resonance imaging (MRI), showing typical lesion morphology, characteristic distribution of lesions, or involvement or specific anatomic structures, can support the diagnosis of MS. But from an imaging perspective a considerable amount of inherited and acquired disorders may manifest with radiologic evidence of DIT, DIS, or both. Hypoxic-ischemic vasculopathy, specially small-vessel disease, inflammatory disorders, vasculitis, and non-MS idiopathic inflammatory disorders, as well as some toxic, metabolic, and infectious disorders, may present mimicking MS on MR examinations and should be included in the differential diagnosis of MS-like lesions. Careful evaluation of associated findings on MRI, the so-called MRI red flags, such as the presence of infarcts, microbleeds, meningeal enhancement, and calcifications among others, are very helpful in suggesting a diagnosis other than MS. Complement MRI findings to patient's history, demographics, and serologic findings are crucial to achieve the correct diagnosis. We will review the most frequent radiologic appearance and differential features from the most frequent MS mimickers.

Download full-text PDF

Source
http://dx.doi.org/10.1016/B978-0-444-52001-2.00012-1DOI Listing

Publication Analysis

Top Keywords

multiple sclerosis
8
inflammatory disorders
8
mri
5
diagnosis
5
mri mimics
4
mimics multiple
4
sclerosis diagnosis
4
diagnosis multiple
4
sclerosis based
4
based demonstration
4

Similar Publications

Anti-CD20 monoclonal antibodies are gaining clinical relevance in the nephrology community due to their demonstrated efficacy and favorable safety profiles across short-, medium-, and long-term use. Initially developed for hematologic malignancies and multiple sclerosis, B-cell depletion therapies are now being investigated across a broader spectrum of autoimmune diseases, including glomerulopathies, both with and without associated podocytopathy. Recent advances have led to the development of novel anti-CD20 agents that are being used not only as potential alternatives to corticosteroids but also as adjunctive therapies in complex clinical settings.

View Article and Find Full Text PDF

Objective: This study aimed to evaluate the effects of various physical therapy interventions on fatigue and quality of life in patients with multiple sclerosis (MS) using a network meta-analysis of randomized controlled trials (RCTs).

Methods: A comprehensive literature search was conducted in PubMed, Web of Science, and Cochrane databases through April 1, 2025. Eligible RCTs compared different exercise interventions in MS patients, focusing on fatigue and quality of life outcomes.

View Article and Find Full Text PDF

High morbidity and mortality associated with human β-coronavirus (CoV) infection highlight the need to determine host responses to infection and develop anti-viral therapies. Gap junction intercellular communication (GJIC), particularly involving Connexin43 (Cx43), is vital for maintaining central nervous system (CNS) homeostasis, and disruption of GJIC is a well-documented pathogenic mechanism among β-coronaviruses. Specifically, murine β-coronavirus, mouse hepatitis virus (MHV-A59) inoculation in the mouse brain causes acute-stage CNS viral spread and chronic neuroinflammatory demyelination while causing pronounced downregulation of Cx43 at the acute stage, reflecting a critical role in CNS pathology.

View Article and Find Full Text PDF

Objective: The objective of this study was to compare the long-term safety profiles of ocrelizumab and rituximab in persons with multiple sclerosis (MS).

Methods: Using retrospective data from the University of California (UC) Health System, we simulated a target clinical trial. The primary cohort from UC San Francisco (UCSF) and a validation cohort from 5 other UC Medical Centers were analyzed.

View Article and Find Full Text PDF